Skip to main content
Explore URMC
menu

Michael Andrew Cummings, M.D.,M.S.

Contact Information

Phone Numbers

Appointment: (585) 275-2171

Administrative: (585) 275-2171

Fax: (585) 335-8697

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Radiation Oncology

Biography

Dr. Cummings is an Assistant Professor of Radiation Oncology at the University of Rochester School of Medicine and Dentistry and completed graduate studies in Cancer Genetics at Roswell Park in Buffalo, NY and his residency training at the University of Rochester.

My practice specializes in head and neck cancers, prostate cancer including brachytherapy, and bladder cancer. There is often no one best approach for any situation, and the goal of any visit is finding how the uniqueness of each person and their case fits into the published evidence and their own expectations, and setting out a treatment plan that meets those goals.

Outside work I am married with two sons who are young enough to still want to spend time with me, and that keeps me quite busy. I enjoy running outdoors, am a part time Cub Scout Den Leader, skiing in the winter, and watching the Sabres and Bills.

Credentials

Specialties

  • Radiation Oncology - American Board of Radiology

Education

2009
MD | Suny Upstate Medical University

Post-doctoral Training & Residency

07/01/2014 - 06/28/2018
Residency in Radiation Oncology at University of Rochester Medical Center

07/01/2013 - 06/30/2014
Internship in Internal Medicine at Suny Upstate Medical University

Awards


Alpha Omega Alpha, Medical Honor Society

Clinical Trials

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (S1806)

Lead Researcher: Michael Andrew Cummings

This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.

View Study Details

Publications

Journal Articles

2/2021
Cummings MA, Ma SJ, Van Der Sloot P, Milano MT, Singh DP, Singh AK. "Squamous cell carcinoma of the head and neck with unknown primary: trends and outcomes from a hospital-based registry." Annals of translational medicine.. 2021 Feb 0; 9(4):284.

2021
Luitje ME; Israel AK; Cummings MA; Giampoli EJ; Allen PD; Newlands SD; Ovitt CE. "Long-term maintenance of acinar cells in human submandibular glands after radiation therapy." International journal of radiation oncology, biology, physics. 2021; 109(4): 1028-1039.

2/25/2020
Milano MT, Bates JE, Budnik J, Qiu H, Hardy S, Cummings MA, Baumgart MA, Maggiore RJ, Mulford DA, Usuki KY. "Risk of brain metastases in T1-3N0 NSCLC: a population-based analysis." . 2020 Feb 25; 9(1):LMT25. Epub 2020 Feb 25.

VIEW ALL PUBLICATIONS